Loading quotes...

Forecast

The analysts' average price target is €140.24 (-1.71%). The median is €146.80 (+2.89%).

Buy	39
Hold	18
Sell	1

News Go to news feed

Gilead Sciences expands lenacapavir access to 14 Latin American and Caribbean countries via PAHO deal

Gilead Sciences struck an agreement with the Pan American Health Organization to create a regional procurement pathway for twice-yearly HIV-prevention drug lenacapavir across 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru. The arrangement could broaden lenacapavir's commercial footprint and supports Gilead's plan to make the drug a major HIV growth driver, with about $1 billion in expected 2026 sales and recent quarter-to-quarter HIV sales gains. Actual revenue growth will depend on country-level regulatory approvals, government adoption and procurement terms, and wider access or local production could depress pricing and margins versus U.S. levels. The deal strengthens long-term volume potential but leaves near-term earnings exposure to timing and pricing risks across individual markets. » More on finance.yahoo.com
Gilead diversifies into oncology and inflammatory medicine, virology remains core

At the Wells Fargo Healthcare Conference, Gilead presented an expanded growth plan with three strategic pillars: virology, oncology and inflammatory medicine, with HIV remaining the core business. The company reported a full pipeline and several upcoming launches in late 2026/2027, highlighted Anito‑cel (CAR‑T) with a differentiated safety profile and strong growth signals in PrEP and TRODELVY revenues. Gilead emphasized the need for selective prioritization within its broad pipeline and plans further data readouts as well as potential partnerships and external transactions. » More on de.investing.com
Assembly Biosciences takes 40% stake in Gilead program; shares rise after-hours

Assembly Biosciences has exercised its option and will assume 40% of U.S. development costs and profits for the helicase–primase inhibitor program against herpes, while Gilead will handle clinical development and commercialization. Assembly secures rights to up to $280 million in milestone payments and tiered royalties outside the U.S.; additionally, a $75 million payment from Gilead in Q4 2026 extends the company’s cash runway to 2029. Lead candidate GS-1179 was selected for further development and provides a phase‑2 catalyst; the shares rose 4.9% in after-hours trading to $37. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Gilead Sciences has already paid €2.16 in dividends. The last payout was in September.

Financials

In the last quarter, Gilead Sciences had revenue of €6.84B and net profit of -€9.2B

(EUR)	June 2026	YoY
Revenue	6.84B	13.81%
Gross profit	5.45B	15.19%
Net profit	-9.2B	653.05%
EBITDA	-8.16B	384.94%

Fundamentals

Metric	Value
Market capitalization	€173.19B
Number of shares	1.24B
52-week high/low	€143.67 - €102.06
Dividend yield	2.03%
Dividends TTM	€2.83
Beta	0.33
P/E ratio	-60.02
PEG ratio	0.40
P/B ratio	16.40
P/S ratio	6.35

Company profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.